投稿一覧に戻る
ティジアナ・ライフ・サイエンシズ【TLSA】の掲示板
-
>>6
Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid.
Long Covid is a health condition characterised by the continuation or development of new symptoms three months after an initial SARS-CoV-2 infection.
ほしにねがいを
>>1
Tiziana Life Sciences plans to assess intranasal foralumab for long Covid
The company expects to advance foralumab to Phase II trials in Q3 2023.